Blackpool CCG medicines optimisation

Blackpool CCG medicines optimisation

Medicines play an important part in promoting well-being, preventing ill health and managing disease. Over 700 million prescription items are dispensed in England each year with a cost approaching £8billion.

Medicines management can be defined in several ways:

  • The clinical, cost-effective, safe and secure handling of medicines
  • A system of processes and behaviours that determines how medicines are used by the NHS and patients
  • Enabling people to make the best possible use of medicines
  • Our goal is to achieve the best health outcomes for patients where medicines are involved.

If you have any medicines queries please contact NHS Blackpool CCG’s medicines management team on 01253 951306 or email blackpool.medicinesoptimisation@nhs.net


 

Click each header to expand its content

Medicines RAG list

Please see the links below for background information on the Red, Amber, Green (RAG) classification in relation to prescribing responsibility and also our RAG list of drugs.

Prescribing position statements

NameSizeHits
28 Day Prescribing 0.3 MB318
Camouflaging Products 0.2 MB107
Cannabis based medicinal products for pain POSITION STATEMENT 0.3 MB248
Clinical Need Low Priority Medicines - General 0.3 MB403
Clinical Need Soluble Analgesics 0.5 MB818
Clinical Need Thickeners Position Statement 0.3 MB387
Commercial sponsorship and joint working with the pharmaceutical industry 0.6 MB224
Denosumab Position Statement 0.3 MB212
E-Cigarettes-Position-Statement-v2.0-FINAL-FOR-LMMG-WEBSITE[1] 0.2 MB232
Edoxaban Position Statement 0.2 MB232
Emollients and Sunscreens 0.2 MB407
Free of Charge (FOC) Medicines schemes 0.3 MB231
Generic Biosimilar Medicines Position Statement 0.2 MB222
Generic Prescribing Guidelines 0.3 MB352
Glucose Monitoring Devices 0.5 MB299
Gluten Free Foodstuffs 0.2 MB250
Health Professionals e-cigarettes briefing 0.2 MB204
Holiday Medication 0.2 MB372
Liothyronine 0.2 MB217
Ophthalmology Macular Pathways 1.1 MB224
Oral Nutritional Supplements (ONS) in care and nursing homes 0.2 MB298
Out of Area Prescribing 0.2 MB167
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus 0.3 MB241
Position Statement OPIOID PRESCRIBING max dose Final Version 1.1 0.1 MB128
Position Statement Sip Feeds 0.4 MB258
Prescribing Nutritional Supplements Post Bariatric Surgery 0.3 MB224
Prescribing of multivitamins and phenylalanine-free amino acid substitutes for adults and children with phenylketonuria (PKU) 0.7 MB207
Prescribing Vitamins And Minerals 0.3 MB190
Prophylactic supply of catheters post pelvic organ prolapse 0.2 MB193
Stoma Care Products - deodorants and air fresheners 0.4 MB260
Trans Anal Irrigation Devices 0.2 MB196
Vitamin D Position Statement 0.2 MB210
Zero Risk Schemes 0.3 MB187

Prescribing guidance

NameSizeHits
Antimicrobial Formulary 2020 0.7 MB89
Antimicrobial Summary additional information 2020 23 KB37
Asthma treatment guideline for children version 0.4 MB107
Axial-Spondyloarthritis-pathway-Version 37 KB145
Blood glucose meters and test strips Type 2 Diabetes V2.3 0.5 MB741
Cannabis-based-medication-desk-guide-Nov-2018 December-Edit 0.6 MB214
Chronic Non-cancer Pain Guidelines 0.7 MB215
Colomycin prescribing information sheet Non CF indications. 0.2 MB171
Constipation-Pathway-Version 0.7 MB804
dementia medicines information sheet 0.3 MB86
Diabetes - Glucagon Like Peptide Contract 0.2 MB239
Diabetes - Home Monitoring of Blood Glucose Levels Guideline 0.2 MB527
DIABETES Algorithm-for-antihyperglycaemic-therapy-in-adults-with-type-II-v1.5[1] 0.5 MB244
Diabetes-self-management-contract 0.5 MB266
Edoxaban Prescribing Tip 68 KB267
Erectile-Dysfunction-Guideline-Version 1.0 MB368
Flash Glucose Monitoring policy - L&SC 0.2 MB180
Gastroenterology-Biologics-Pathway-Version 0.4 MB240
Good-practice-guidelines-for-Gender-Dysphoria 0.6 MB191
Gout-Prescribing-Guidance-Version-1.2-FOR-WEBSITE 0.7 MB447
Guidance for Prescribing Second Generation Long Acting Antipsychotic Injections 0.6 MB155
Headache Management Guideline for Adults 0.7 MB222
Insulin Toujeo Information Sheet and Good Practice Guide 0.3 MB247
Interim Gender Dysphoria protocol 0.6 MB188
Lancashire and South Cumbria Self-Care and Acces to OTC Medicines – Temp... 83 KB96
LMMG-Psoriasis-guideline-FOR-WEBSITE 0.5 MB1307
LSCMMG OTC Items that Should not be Routinely Prescribed in Primary Care... 0.2 MB124
Management-of-Behavioural-and-Psychological-Symptoms-of-Dementia-Primary-Care-Summary-Document 0.2 MB242
Neuropathic Pain Guidance (Version 1.2) 0.9 MB393
NWC-SCN01-Clinical-Practice-Summary-Palliative-Care-Final-version 0.6 MB230
Pathway For The Prevention Of Stroke And Systemic Embolism In Non Valvular Atrial Fibrillation Plus TIA 0.8 MB194
Prescription-Management-of-Stoma-and-Continence-Products-Version-1.1-FINAL-FOR-WEBSITE 0.6 MB309
Primary Care Good Prescribing Guide 0.6 MB728
Primary Care Responsibilities in Prescribing and Monitoring Hormone Therapy 0.3 MB196
Psoriasis LMMG Biologic and High Cost Drug Commissioning Pathway v-1.6[1] 0.4 MB317
Psoriatic-Arthritis-Recommended-Treatment-Pathway-Version 0.3 MB262
RA-High-Cost-Drugs-Pathway-v 0.2 MB224
Restless Legs Syndrome guidelines 0.3 MB159
Rheumatoid Arthritis Pathway Guideline 0.1 MB119
SIP Feeds 0.1 MB282
Trans male prescribing information sheet 0.2 MB143
Trans-female-gender-dysphoria-prescribing-information-sheet-version-1.1[1] 0.2 MB109
Wound care formulary 8.2 MB536

SHARED CARE: Guidelines and information documents

Where shared care has been agreed between prescribers, this section includes documents to support clinicians in clarifying their responsibilities around prescribing and drug/patient monitoring, where relevant.

DMARDs-Shared-Care-Agreement-V1.1 (docx | 0.1 MB)

For drugs listed in the GP+ scheme below, please refer to the GP+ specification (Standard 10: Shared Care). Since drugs may be added to the list in-year, the list below will be the most up-to-date, rather than those listed in the current 2017/18 GP+ document.

Drugs included in GP+ scheme

Drugs not included in GP+ scheme

Patient Group Directions

A Patient Group Direction (PGD) is a written direction that allows the supply and/or administration of a specified medicine(s), by named authorised health professionals, to a well-defined group of patients requiring treatment for a specific condition. The patient must always fit the defined criteria and organisations must ensure that healthcare professionals supplying and/or administering medicines under a PGD are fully trained, competent individuals who are authorised to do so.

Organisations must be in possession of PGDs that are appropriately signed and fully authorised, unsigned copies are not the legal document and are for information purposes only.

Cumbria and Lancashire CCGs have a collaborative arrangement to produce the PGDs for the national vaccination programme.

Vaccine and immunisation PGDs: The signed copies of these PGDs have been distributed to organisations and GP practices. Each organisation or practice is required to keep the signed copy and ensure all health professionals who will be working under it are authorised and have signed the second page under the managerial content section. The documents at the following link are for information only and are not the legal document: www.lancsmmg.nhs.uk/pgds

Patient information leaflets

Primary Care Rebate Schemes

Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.

Current Primary Care Rebate Schemes in place:

  • Clenil Modulite (Beclometasone) – Started July 2019
  • Fencino (Fentanyl) – Started October 2018
  • Firmagon (Degarelix) – Started September 2016
  • Januvia (Sitagliptin)  – Started September 2018
  • Lixiana (Edoxaban) – Started October 2018
  • Longtec (Oxycodone SR) – Started July 2019
  • Sereflo (Fluticasone / Salmeterol) – Started June 2019
  • Seretide (Fluticasone / Salmeterol) – Started January 2018
  • Spiolto (Tiotropium + Olodaterol) – Started October 2018
  • Xarelto (Rivaroxaban) – Started July 2019
  • Zoladex (Goserelin) – Started January 2019

Last updated on 18 December 2019 at 11:11 by Senior communications and engagement officer N